NuVasive develops and commercializes minimally invasive medical devices and products for the surgical treatment of spinal disorders.Read more
NuVasive's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 5.9B. Over the last four quarters, NuVasive's revenue has grown by 14.6%. Specifically, in Q2 2022's revenue was $310.5M; in Q1 2022, it was $290.8M; in Q4 2021, it was $302.1M; in Q3 2021, NuVasive's revenue was $270.8M.